Authors’ Reply to Wang et al., “Comment on ‘Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clinical Trial’”
- DOI
- 10.1007/s40257-024-00896-7
- Published
- 2024-10-15
- Container
- American Journal of Clinical Dermatology
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s40257-024-00896-7,
title = {Authors’ Reply to Wang et al., “Comment on ‘Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clinical Trial’”},
author = {Yukari Okubo and Satomi Kobayashi and Masamoto Murakami and Shigetoshi Sano and Natsuko Kikuta and Yoshiumi Ouchi and Tadashi Terui},
year = {2024},
journal = {American Journal of Clinical Dermatology},
doi = {10.1007/s40257-024-00896-7},
url = {https://doi.org/10.1007/s40257-024-00896-7}
}RIS
TY - JOUR TI - Authors’ Reply to Wang et al., “Comment on ‘Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clinical Trial’” AU - Yukari Okubo AU - Satomi Kobayashi AU - Masamoto Murakami AU - Shigetoshi Sano AU - Natsuko Kikuta AU - Yoshiumi Ouchi AU - Tadashi Terui PY - 2024 JO - American Journal of Clinical Dermatology DO - 10.1007/s40257-024-00896-7 UR - https://doi.org/10.1007/s40257-024-00896-7 ER -
APA
Okubo, Y., Kobayashi, S., Murakami, M., Sano, S., Kikuta, N., Ouchi, Y., & Terui, T. (2024). Authors’ Reply to Wang et al., “Comment on ‘Efficacy and Safety of Brodalumab, an Anti‑interleukin‑17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16‑Week Results of a Randomized Clinical Trial’”. American Journal of Clinical Dermatology. https://doi.org/10.1007/s40257-024-00896-7
Source records
- crossref · retrieved 2026-09-27T11:00:44.908Z